Skip to main content
Top
Published in: BMC Cancer 1/2005

Open Access 01-12-2005 | Research article

Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA

Authors: Richard M Hoffman, S Noell Stone, David Espey, Arnold L Potosky

Published in: BMC Cancer | Issue 1/2005

Login to get access

Abstract

Background

The advent of prostate specific antigen (PSA) testing in the United States of America (USA) has led to a dramatic increase in the incidence of prostate cancer in the United States as well as the number of men undergoing aggressive treatment with radical prostatectomy and radiation therapy. We compared patient characteristics and treatment selection between American men with screening-detected versus clinically diagnosed prostate cancers.

Methods

We evaluated 3,173 men with prostate cancer in the USA. Surveys and medical records provided information on demographics, socioeconomic status, comorbidities, symptoms, tumor characteristics, and treatment. We classified men presenting with symptoms of advanced cancer – bone pain, weight loss, or hematuria – as "clinically diagnosed"; asymptomatic men and those with only lower urinary tract symptoms were considered "screening-detected." We used multivariate analyses to determine whether screening predicted receiving aggressive treatment for a clinically localized cancer.

Results

We classified 11% of cancers as being clinically diagnosed. Men with screening-detected cancers were more often non-Hispanic white (77% vs. 65%, P < 0.01), younger (36% < 65 years vs. 25%, P ≤ 0.01), better educated (80% ≥ high school vs. 67%, P < 0.01), healthier (18% excellent health vs. 10%, P < 0.01), and diagnosed with localized disease (90% vs. 75%, P < 0.01). Men with screening-detected localized cancers more often underwent aggressive treatment, 76% vs. 70%, P = 0.05.

Conclusion

Most cancers were detected by screening in this American cohort. Appropriately, younger, healthier men were more likely to be diagnosed by screening. Minority status and lower socio-economic status appeared to be screening barriers. Screening detected earlier-stage cancers and was associated with receiving aggressive treatment.
Literature
1.
go back to reference Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993, 119: 914-23.CrossRefPubMed Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993, 119: 914-23.CrossRefPubMed
2.
go back to reference American Urological Association: Early detection of prostate cancer and use of transrectal ultrasound. American Urological Association 1992 Policy Statement Book. 1992, Baltimore, MD: Williams & Wilkins, American Urological Association: Early detection of prostate cancer and use of transrectal ultrasound. American Urological Association 1992 Policy Statement Book. 1992, Baltimore, MD: Williams & Wilkins,
3.
go back to reference Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993, 43: 42-6.CrossRefPubMed Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993, 43: 42-6.CrossRefPubMed
4.
go back to reference Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, Gilliland F, Hankey B, Kolonel LN, Kosary C, Ross R, Severson R, West D: Prostate Cancer Trends 1973–1995. 1999, Bethesda, MD: SEER Program, National Cancer Institute; Report No.: NIH Pub. No. 99-4543 Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, Gilliland F, Hankey B, Kolonel LN, Kosary C, Ross R, Severson R, West D: Prostate Cancer Trends 1973–1995. 1999, Bethesda, MD: SEER Program, National Cancer Institute; Report No.: NIH Pub. No. 99-4543
5.
go back to reference Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, eds: SEER Cancer Statistics Review, 1975–2001. 2004, National Cancer Institute. Bethesda, MD Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK, eds: SEER Cancer Statistics Review, 1975–2001. 2004, National Cancer Institute. Bethesda, MD
6.
go back to reference Mettlin C: Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974–1993. Prostate. 1997, 32: 221-6. 10.1002/(SICI)1097-0045(19970801)32:3<221::AID-PROS9>3.0.CO;2-N.CrossRefPubMed Mettlin C: Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974–1993. Prostate. 1997, 32: 221-6. 10.1002/(SICI)1097-0045(19970801)32:3<221::AID-PROS9>3.0.CO;2-N.CrossRefPubMed
7.
go back to reference Lu-Yao GL, Friedman M, Yao SL: Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997, 157: 2219-22. 10.1097/00005392-199706000-00055.CrossRefPubMed Lu-Yao GL, Friedman M, Yao SL: Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol. 1997, 157: 2219-22. 10.1097/00005392-199706000-00055.CrossRefPubMed
8.
go back to reference Mettlin CJ, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Somers WJ, Toi A: Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1997, 80: 1814-7. 10.1002/(SICI)1097-0142(19971101)80:9<1814::AID-CNCR20>3.0.CO;2-7.CrossRefPubMed Mettlin CJ, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Somers WJ, Toi A: Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1997, 80: 1814-7. 10.1002/(SICI)1097-0142(19971101)80:9<1814::AID-CNCR20>3.0.CO;2-7.CrossRefPubMed
9.
go back to reference Yan Y, Carvalhal GF, Catalona WJ, Young JD: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000, 88: 1122-30.CrossRefPubMed Yan Y, Carvalhal GF, Catalona WJ, Young JD: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000, 88: 1122-30.CrossRefPubMed
10.
go back to reference Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH: The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol. 1999, 161: 1192-8. 10.1097/00005392-199904000-00042.CrossRefPubMed Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schroder FH: The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol. 1999, 161: 1192-8. 10.1097/00005392-199904000-00042.CrossRefPubMed
11.
go back to reference Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS: Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999, 91: 1719-24. 10.1093/jnci/91.20.1719.CrossRefPubMed Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS: Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999, 91: 1719-24. 10.1093/jnci/91.20.1719.CrossRefPubMed
12.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-83. 10.1016/0021-9681(87)90171-8.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40: 373-83. 10.1016/0021-9681(87)90171-8.CrossRefPubMed
13.
go back to reference Prostate: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 1997, Philadelphia, Pa: Lippincott-Raven, 219-24. 5 Prostate: American Joint Committee on Cancer: AJCC Cancer Staging Manual. 1997, Philadelphia, Pa: Lippincott-Raven, 219-24. 5
14.
go back to reference Hennekens CH, Buring JE: Epidemiology in Medicine. 1987, Boston: Little, Brown Hennekens CH, Buring JE: Epidemiology in Medicine. 1987, Boston: Little, Brown
15.
go back to reference Chapple CR: Lower urinary tract symptoms suggestive of benign prostatic obstruction – Triumph: design and implementation. Eur Urol. 2001, 39 (Suppl): 31-6. 10.1159/000052565.CrossRefPubMed Chapple CR: Lower urinary tract symptoms suggestive of benign prostatic obstruction – Triumph: design and implementation. Eur Urol. 2001, 39 (Suppl): 31-6. 10.1159/000052565.CrossRefPubMed
16.
go back to reference Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995, 13: 93-100.PubMed Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol. 1995, 13: 93-100.PubMed
17.
go back to reference Desch CE, Penberthy L, Newschaffer CJ, Hillner BE, Whittemore M, McClish D, Smith TJ, Retchin SM: Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996, 34: 152-62. 10.1097/00005650-199602000-00007.CrossRefPubMed Desch CE, Penberthy L, Newschaffer CJ, Hillner BE, Whittemore M, McClish D, Smith TJ, Retchin SM: Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996, 34: 152-62. 10.1097/00005650-199602000-00007.CrossRefPubMed
18.
go back to reference Graubard BI, Korn EL: Predictive margins with survey data. Biometrics. 1999, 55: 652-9. 10.1111/j.0006-341X.1999.00652.x.CrossRefPubMed Graubard BI, Korn EL: Predictive margins with survey data. Biometrics. 1999, 55: 652-9. 10.1111/j.0006-341X.1999.00652.x.CrossRefPubMed
19.
go back to reference Nelson DE, Bland S, Powell-Griner E, Klein R, Wells HE, Hogelin G, Marks JS: State trends in health risk factors and receipt of clinical preventive services among US adults during the 1990s. JAMA. 2002, 287 (20): 2659-67. 10.1001/jama.287.20.2659.CrossRefPubMed Nelson DE, Bland S, Powell-Griner E, Klein R, Wells HE, Hogelin G, Marks JS: State trends in health risk factors and receipt of clinical preventive services among US adults during the 1990s. JAMA. 2002, 287 (20): 2659-67. 10.1001/jama.287.20.2659.CrossRefPubMed
20.
go back to reference Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA. 2003, 289 (11): 1414-20. 10.1001/jama.289.11.1414.CrossRefPubMed Sirovich BE, Schwartz LM, Woloshin S: Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA. 2003, 289 (11): 1414-20. 10.1001/jama.289.11.1414.CrossRefPubMed
21.
go back to reference Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001, 93: 388-95. 10.1093/jnci/93.5.388.CrossRefPubMed Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001, 93: 388-95. 10.1093/jnci/93.5.388.CrossRefPubMed
22.
go back to reference Baquet CR, Horm JW, Gibbs T, Greenwald P: Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991, 83: 551-7.CrossRefPubMed Baquet CR, Horm JW, Gibbs T, Greenwald P: Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991, 83: 551-7.CrossRefPubMed
23.
go back to reference Liff JM, Chow W-H, Greenberg RS: Rural-urban differences in stage at diagnosis. Possible relationship to cancer screening. Cancer. 1991, 67: 1454-9.CrossRefPubMed Liff JM, Chow W-H, Greenberg RS: Rural-urban differences in stage at diagnosis. Possible relationship to cancer screening. Cancer. 1991, 67: 1454-9.CrossRefPubMed
24.
go back to reference Pamies RJ, Woodard LJ: Cancer in socioeconomically disadvantaged populations. Primary Care. 1992, 19: 443-50.PubMed Pamies RJ, Woodard LJ: Cancer in socioeconomically disadvantaged populations. Primary Care. 1992, 19: 443-50.PubMed
25.
go back to reference Robinson SB, Ashley M, Haynes MA: Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc. 1996, 88: 241-6.PubMedPubMedCentral Robinson SB, Ashley M, Haynes MA: Attitudes of African Americans regarding screening for prostate cancer. J Natl Med Assoc. 1996, 88: 241-6.PubMedPubMedCentral
26.
go back to reference Morton RA: Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994, 44: 637-45. 10.1016/S0090-4295(94)80196-7.CrossRefPubMed Morton RA: Racial differences in adenocarcinoma of the prostate in North American men. Urology. 1994, 44: 637-45. 10.1016/S0090-4295(94)80196-7.CrossRefPubMed
27.
go back to reference American College of Physicians: Screening for prostate cancer. Ann Intern Med. 1997, 126: 480-4.CrossRef American College of Physicians: Screening for prostate cancer. Ann Intern Med. 1997, 126: 480-4.CrossRef
28.
go back to reference Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002, 137: 917-29.CrossRefPubMed Harris R, Lohr KN: Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002, 137: 917-29.CrossRefPubMed
29.
go back to reference Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL: Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Med Care. 2000, 38: 847-57. 10.1097/00005650-200008000-00008.CrossRefPubMed Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL: Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study. Med Care. 2000, 38: 847-57. 10.1097/00005650-200008000-00008.CrossRefPubMed
Metadata
Title
Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA
Authors
Richard M Hoffman
S Noell Stone
David Espey
Arnold L Potosky
Publication date
01-12-2005
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2005
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-5-27

Other articles of this Issue 1/2005

BMC Cancer 1/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine